Mouse Anti-IDUA Recombinant Antibody (9H133) (CBMAB-I1840-YY)

Iduronidase, Alpha-L-

This gene encodes an enzyme that hydrolyzes the terminal alpha-L-iduronic acid residues of two glycosaminoglycans, dermatan sulfate and heparan sulfate. This hydrolysis is required for the lysosomal degradation of these glycosaminoglycans. Mutations in this gene that result in enzymatic deficiency lead to the autosomal recessive disease mucopolysaccharidosis type I (MPS I).

Iduronidase, Alpha-L-

Chondroitin sulfate catabolic process Source: Reactome
Dermatan sulfate catabolic process Source: UniProtKB
Disaccharide metabolic process Source: ProtInc
Glycosaminoglycan catabolic process Source: Reactome
Heparin catabolic process Source: MGI

Lysosome

Mucopolysaccharidosis 1H (MPS1H):
A severe form of mucopolysaccharidosis type 1, a rare lysosomal storage disease characterized by progressive physical deterioration with urinary excretion of dermatan sulfate and heparan sulfate. Patients with MPS1H usually present, within the first year of life, a combination of hepatosplenomegaly, skeletal deformities, corneal clouding and severe mental retardation. Obstructive airways disease, respiratory infection and cardiac complications usually result in death before 10 years of age.
Mucopolysaccharidosis 1H/S (MPS1H/S):
A form of mucopolysaccharidosis type 1, a rare lysosomal storage disease characterized by progressive physical deterioration with urinary excretion of dermatan sulfate and heparan sulfate. MPS1H/S represents an intermediate phenotype of the MPS1 clinical spectrum. It is characterized by relatively little neurological involvement, but most of the somatic symptoms described for severe MPS1 develop in the early to mid-teens, causing considerable loss of mobility.
Mucopolysaccharidosis 1S (MPS1S):
A mild form of mucopolysaccharidosis type 1, a rare lysosomal storage disease characterized by progressive physical deterioration with urinary excretion of dermatan sulfate and heparan sulfate. Patients with MPS1S may have little or no neurological involvement, normal stature and life span, but present development of joints stiffness, mild hepatosplenomegaly, aortic valve disease and corneal clouding.

N-glycosylation at Asn-372 contributes to substrate binding and is required for full enzymatic activity.